• Investing Insights & Exclusive Offers → Get Our FREE “Market Brief”
    Sign-up for our free weekly newsletter. Get unparalleled investing insights and exclusive Summer Sale discounts on Hedgeye research.

    Disclaimer: By joining our email marketing list you agree to receive marketing emails from Hedgeye. You may unsubscribe at any time by clicking the unsubscribe link in one of the emails. Use of Hedgeye and any other products available through hedgeye.com are subject to our Terms Of Service and Privacy Policy

Watch the replay below

Healthcare analyst Tom Tobin and Health Policy analyst Emily Evans  review their best stock ideas, major healthcare themes and more. They will also take questions from the live viewer audience after their prepared remarks.

Prior to news of COVID-19 re-acceleration in the early days of the re-opening, we spoke with a leading academic epidemiologist heavily involved in COVID-19 testing. Our contact viewed a #SecondWave as likely already underway in the United States with more to come, citing similar cases in Iran and Poland. In the near- term, it seems likely that the market will be placed between a concerned public without a vaccine and an economy that cannot afford a second lock down. On Monday’s Health Care Check Up, we will cover:

  • Robin Hood | As many have caught on, there has been an influx of retail investors in the past months as a result of targeted advertising and $0 commission fees. We will take a closer look into the ownership trends by Robin Hood accounts of our Position Monitor names.
  • #SecondWave | While a national re-acceleration seems unlikely, insights from our academic epidemiologist and policy analyst, Emily Evans, seem to guarantee local and regional outbreaks of COVID-19 throughout the phased re-opening of the United States. We'll present our field notes, some uncomfortable signs of a re-acceleration, and the hopeful data suggesting it might not be so bad.
  • COVID-19 Testing | Weekly testing remains substantially lower than the 5 to 20 million test recommended by the academic community. Along with capacity concerns for some large testing names, we'll review the initial findings and data from our proprietary testing data.
  • Screen Results - HRC | #MacroQuads matter, but so do fundamentals. We continue to find success screening our universe for Long and Short candidates using consensus estimate trends and the vectors of growth and acceleration. We have begun work on Hill-Rom after our Fundamental Equity Screen flagged it as a short earlier this week.

CLICK HERE to access the associated slides.